Foresight Diagnostics to demonstrate utility of PhasED-Seq technology at ICML meeting

Foresight Diagnostics, the emerging leader in the monitoring of blood-based lymphoma diseases, announced today that the clinical performance of its Minimal Residual Disease Detection Platform (MRD) in Diffuse B-Cell Large Cell Lymphoma (DLBCL) has been unveiled at the 16th International Conference on Malignant Lymphoma will (ICML) June 18-22, 2021. The oral presentation will demonstrate the utility of Foresight Diagnostics’ proprietary PhasED-Seq technology to improve MRD detection rates in DLBCL patients in low-disease environments.

Foresight’s MRD testing platform can detect relapsing disease 200 days earlier than current methods in DLBCL patients receiving first-line therapy. We believe that such early detection is the future standard for ctDNA-driven patient monitoring and treatment in the clinic and for applications in drug development. We are proud that our abstract was selected for oral presentation at this year’s ICML meeting and we look forward to sharing this powerful data. “

David Kurtz, MD, PhD, professor at Stanford University and co-founder of Foresight Diagnostics

Kurtz will moderate the lecture at the ICML. The presentation entitled “Phased variants improve the detection of minimal residual diseases in DLBCL at the end of therapy” will be held during session 3: Aggressive Lymphomas (Channel 3) on Sunday, June 20th at 5:45 pm-7:15pm ( CEST).

The detection of circulating tumor DNA (ctDNA) has a prognostic value in DLBCL and has the potential to change the treatment of lymphoma in the clinic. However, detection is still challenging in low disease burden conditions with existing methods, such as MRD detection at the end of therapy.

Foresight’s talk at ICML will introduce Phased Variant Enrichment & Detection Sequencing (PhasED-Seq), Foresight’s proprietary ctDNA technology that uses a novel class of somatic changes called Phased Variants (PVs). By identifying and tracking PVs, PhasED-Seq enables ctDNA-MRD detection down to parts per million and offers a sensitivity that is significantly better than SNV-based methods. The talk will also show that PVs are widespread in B-cell lymphomas and occur in stereotypical locations, enabling an “off-the-shelf” approach to variant monitoring that requires neither tumor tissue nor patient-specific adjustments.

“Although many patients with diffuse large B-cell lymphoma are cured with standard therapies, there remains a great need to precisely identify those who are not cured and who would benefit from new therapeutic strategies,” said Mark Lee, MD, PhD, board member von Foresight, founding director at GRAIL and most recently SVP and Global Head of Personalized Healthcare at Genentech. “The improved sensitivity for ctDNA-based MRD detection during and after treatment demonstrates the potential of PhasED-Seq as a new standard for lymphoma MRD applications such as MRD-adapted clinical trials.”

Foresight Diagnostics recently announced $ 12.5 million in Series A funding to accelerate the commercialization of PhasED-Seq technology and also presented clinical performance data on PhasED-Seq at the American Society of’s 2021 annual meeting Clinical Oncology (ASCO). Foresight’s first commercially available testing offering will be a CLIA-validated B-cell lymphoma MRD assay, and the company is initiating retrospective and prospective multi-partner clinical trials to evaluate the assay’s utility in patients with a variety of malignant B-cell Assess cell disorders.